Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.
Saved in:
| Title: | Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry. |
|---|---|
| Authors: | Lockshin B; US Dermatology Partners, 15245 Shady Grove Road, Suite 480, Rockville, MD, 20850, USA. blockshin@dermassociates.com., Harrison RW; CorEvitas, LLC, Waltham, MA, USA., McLean RR; CorEvitas, LLC, Waltham, MA, USA., Crabtree MM; CorEvitas, LLC, Waltham, MA, USA., Konicek BW; Eli Lilly and Company, Indianapolis, IN, USA., Zhu B; Eli Lilly and Company, Indianapolis, IN, USA., Malatestinic WN; Eli Lilly and Company, Indianapolis, IN, USA., Atiya B; Eli Lilly and Company, Indianapolis, IN, USA., Murage MJ; Eli Lilly and Company, Indianapolis, IN, USA., Burge RT; Eli Lilly and Company, Indianapolis, IN, USA. |
| Source: | Dermatology and therapy [Dermatol Ther (Heidelb)] 2022 Dec; Vol. 12 (12), pp. 2797-2815. Date of Electronic Publication: 2022 Nov 04. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Healthcare Communications Country of Publication: Switzerland NLM ID: 101590450 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8210 (Print) NLM ISO Abbreviation: Dermatol Ther (Heidelb) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2193-8210 |
|---|---|
| DOI: | 10.1007/s13555-022-00834-7 |
